Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2025-06-23 Report Publication Anno…
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
Report Publication Announcement Classification · 95% confidence The document is an 'Immediate Report' filed under Regulation 4 of the Securities Regulations, specifically mentioning it is a '6K' filing (which is an SEC form for foreign private issuers, often used for material events). The text explicitly states: "Attached hereto is a report on*6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress* ea024614501-6k_purpleEDGAR2_Bannerless_isa.pdf". Since the document itself is short (2259 chars) and serves primarily to announce the publication of an attached report (the 6K content), it fits the definition of a Report Publication Announcement (RPA) or, given its regulatory nature and lack of a more specific category, potentially a general Regulatory Filing (RNS). However, RPA is specifically for announcing the publication of reports. Since this is an announcement of a specific material event report (6K), and RPA covers the announcement of report publication, RPA is the most precise fit among the options for this wrapper document.
2025-06-23 English
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
Regulatory Filings Classification · 96% confidence The document is explicitly titled 'FORM 6-K' and is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934'. This form is used to report material events occurring between quarterly reports. The content is a press release announcing the initiation of a Phase 2 clinical study for a drug (NT219). While it contains detailed information, the primary filing wrapper is the Form 6-K, which is a periodic/current report for foreign private issuers. Among the provided codes, 'IR' (Interim/Quarterly Report) is the closest analogue for comprehensive periodic reporting, but Form 6-K is a specific SEC filing type. Since the provided definitions do not include a specific code for Form 6-K, and this document is a comprehensive report of material events (not just a short announcement of a report), it best fits the general category of a comprehensive periodic report or a significant regulatory filing. Given the options, and recognizing that Form 6-K often contains material updates similar to an Earnings Release (ER) or Interim Report (IR) but is a distinct filing, I must choose the best fit. Since it details clinical trial initiation and scientific updates, it is more substantial than a simple ER. However, Form 6-K is fundamentally a regulatory filing used to disseminate material, non-scheduled information. Since 'RNS' (Regulatory Filings) is the fallback for miscellaneous filings that don't fit elsewhere, and Form 6-K is not explicitly listed (like 10-K), RNS is the most appropriate general regulatory category for this specific SEC form type that isn't covered by the other specific codes (like 10-K, ER, IR). The document length (15,793 chars) confirms it is the report itself, not just an announcement of a report.
2025-06-17 English
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
Report Publication Announcement Classification · 98% confidence The document explicitly states it is an 'Immediate Report' under Israeli Securities Authority regulations, referencing a '6K' filing format, which is typically used by foreign private issuers to report material events to the SEC. The text contains a clear announcement headline ('Purple Biotech Announces Initiation of Phase 2 Study...') and then states, 'Attached hereto is a report on*6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer*'. Since the document itself is short (2171 chars) and serves primarily to announce the publication of a separate, attached report (the 6K PDF), it fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K, IR, or ER, but the announcement of the filing.
2025-06-17 English
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
Regulatory Filings Classification · 99% confidence The document is a press release from Purple Biotech announcing that a poster presentation on their CAPTN-3 platform will be featured at the EACR 2025 conference. It details the abstract number, title, session, date, and presenting author. This type of announcement, which publicizes participation in an external scientific or industry event (like a conference presentation), does not fit neatly into the defined financial reporting categories (10-K, ER, IR, etc.). It is a general corporate update related to R&D progress and investor relations, but it is not a formal financial report, management change, or dividend notice. Given the options, the most appropriate fallback category for a specific, non-standard regulatory or corporate announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it serves as a general announcement mechanism for material, non-standard corporate news.
2025-06-04 English
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
Report Publication Announcement Classification · 95% confidence The document is very short (2185 characters) and explicitly states it is an 'Immediate Report' under Israeli regulations, referencing an attached PDF file titled 'ea024462-pr_purplebiotechltdDRAFT1i_isa.pdf'. The content is a press release headline: 'PR:Purple Biotech Announces Poster Presentation at EACR 2025...'. This structure—a brief announcement referencing an attached document or news item—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content is a specific press release about a scientific presentation, and it is not a comprehensive report (like 10-K or IR), RPA is the most appropriate classification, as it announces the publication of information/news. Given the context of regulatory filings, RNS is also a strong candidate, but RPA specifically covers the announcement of report publication.
2025-06-04 English
Purple Biotech Reports First Quarter 2025 Financial Results
Earnings Release Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed 'For the month of May 2025'. It contains the press release titled 'Purple Biotech Reports First Quarter 2025 Financial Results'. A Form 6-K is used by Foreign Private Issuers to report material events that occur between 6-K filings, often including earnings releases. Since the core content is the announcement of quarterly financial results (First Quarter 2025 Financial Results), the most appropriate classification among the provided options is 'Earnings Release' (ER). Although it is filed on a 6-K, the *content* being reported is the ER. If the document were merely an announcement *about* the release, RPA would apply, but this document contains the full results summary and financial tables, making it the actual Earnings Release content, even if wrapped in a 6-K filing structure. Q1 2025
2025-05-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.